
The ability to exploit the properties of bioactive and nutraceutical compounds incorporated in functional food and oral delivery products depends on developing appropriate strategies to enable their timely release in aqueous solvents. Unfortunately, many bioactive compounds are insoluble or poorly soluble in water, restricting their bioavailability in existing delivery systems. Fast-dissolving structures can be produced from water-soluble encapsulating polymers and biopolymers when coupled with innovative manufacturing techniques, some of which are repurposed from the textile and coatings industries. This article systematically reviews existing and emerging fast-dissolving oral delivery structures from the perspective of food science and technology, exploring enabling manufacturing technologies and the underlying dissolution mechanisms. The focus of this article includes all fast-dissolving systems used in food and drug applications, addressing the limited availability of these systems in current literature. Electrospinning is a crucial technique introduced in this paper due to its compatibility with various polymers and nutraceuticals. This makes it suitable for industrial-scale production using multi-nozzle setups or needle electrospinning. Recent developments in the area of fast-dissolving techniques will guide future bioengineering of oral delivery products containing bioactive compounds for functional foods, without compromising bioavailability or shelf life.
The present study provides a comprehensive phytochemical and bioactivity evaluation of Tropaeolum majus leaf extracts using Caenorhabditis elegans as an alternative in vivo model. Qualitative phytochemical screening confirmed the presence of phenolics and flavonoids in all extracts, while HPTLC analysis revealed complex chemical profiles. LC–MS characterization of the ethyl acetate extract (TMEA) identified diverse phenolic acids, including p-coumaric, caffeic, and sinapic acids, along with flavonoids such as rosmarinic acid, rutin, and myricetin. Quantitative analysis demonstrated the highest total phenolic content (2.1% GAE w/w) and hydroxy radical scavenging activity (23.90 ± 0.25 eq. AA mM/g extract) in the ethyl acetate extract, while ABTS scavenging activity was moderate but consistent among extracts, indicating broad-spectrum antioxidant potential. Toxicity assessment in C. elegans revealed higher mortality with TMEA and TMA, whereas ethanol (TME) and hexane (TMH) extracts exhibited lower toxicity. Chemotaxis assays showed concentration-dependent attraction at sublethal doses and avoidance at higher concentrations. The H₂DCFDA assay for detecting ROS indicated that TMEA showed maximum ROS scavenging activity, with a concentration of 150 µg/mL, followed by TMH, while TME and TMA had moderate antioxidant activity against ROS. The fluorescence-based assay for analyzing lipids revealed that glucose considerably caused an increase in the accumulation of lipids in C. elegans. In the case of the extracts analyzed, TMH (concentration of 150 µg/mL) was the most effective one for lowering lipids, followed by TMEA.
Metabolic dysfunction-associated steatotic liver disease (MASLD) affects ~25–30% of adults worldwide and remains a major clinical challenge due to limited effective pharmacotherapies. We evaluated the therapeutic potential of four Indian medicinal plants - Phyllanthus niruri (PN), Terminalia chebula (TC), Tinospora cordifolia (Tino), and Andrographis paniculata (AP) - administered individually and as a formulation, in a high-fat high-fructose (HFHF) diet-induced murine model of MASLD. Male C57BL/6 mice were fed an HFHF diet for 12 weeks to induce metabolic dysfunction and early-stage MASLD, followed by 8 weeks of oral treatment with individual extracts, the formulation, or Saroglitazar (reference drug). Histological assessment was performed in a blinded manner, alongside biochemical and gene expression analyses. Complementary in vitro studies (HepG2, THP-1, and LX-2) provided mechanistic support. HFHF feeding induced steatosis, insulin resistance, and inflammation without overt fibrosis. Both individual extracts and the formulation improved multiple metabolic and hepatic parameters. AP and TC demonstrated notable effects on glycemic control and lipid metabolism. The formulation demonstrated broader improvements across selected endpoints, with effects comparable to saroglitazar for some parameters. Gene expression analyses indicated modulation of pathways related to lipid metabolism, inflammation and fibrogenic signalling, although these findings are associative. In vitro studies supported effects on lipid accumulation and inflammatory signalling with higher concentrations of AP showing reduced cell viability. Overall, these findings support the multi-targeted potential of these botanicals in MASLD, requiring further studies on standardisation, pharmacokinetics, safety and clinical translational.
Metabolic disorders, including type 2 diabetes mellitus, obesity, and metabolic syndrome, represent major global health challenges due to their increasing prevalence and association with cardiovascular and other chronic diseases. Although conventional pharmacological therapies are effective, their long-term use may be limited by adverse effects, toxicity concerns, and tolerability issues, highlighting the need for complementary therapeutic strategies. Essential oils derived from commonly used herbs and spices have gained attention for their potential role in metabolic health because of their diverse bioactive constituents and favourable safety profiles. This review evaluates the therapeutic potential of essential oils obtained from herbs and spices, focusing on their chemical composition, mechanisms of action, and evidence from preclinical and clinical studies. Key bioactive compounds, including cinnamaldehyde, carvacrol, thymol, eugenol, and thymoquinone, exhibit promising antidiabetic, anti-obesity, and lipid-regulating effects through antioxidant, anti-inflammatory, insulin-sensitising, and metabolic regulatory pathways. Limited clinical studies have reported beneficial effects of essential oils such as garlic and cumin oil on glycemic control and lipid metabolism. However, the current evidence base remains largely dependent on animal studies and small-scale clinical trials. Further well-designed clinical investigations are required to establish efficacy, safety, optimal dosing, and long-term therapeutic applicability in the management of metabolic disorders.